Patient preference for a long-acting recombinant FSH product in ovarian hyperstimulation in IVF: a discrete choice experiment

Wijngaard, Lotte van den; Rodijk, I.C.M.; Veen, Fulco van der; Erven, M.H.W. Gooskens-van; Koks, Carolien A.M.; Verhoeve, Harold R.; Mol, Ben Willem J.; Wely, Madelon van; Mochtar, Monique H.

doi:10.1093/humrep/deu307

Cited by 21 publications

(21 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A number of factors such as psychological burden, physical challenge, depersonalized care, and complex injection protocol tend to impair treatment adherence 2–4. Efficacy (pregnancy rate), tolerability (reaction to injection pain), and convenience (dosing accuracy, ease of use, and number of injections) have been the primary points of concern for patients when choosing self-administered injection devices for IVF treatment 5–11…”

Section: Introductionmentioning

confidence: 99%

Analysis of patient and nurse preferences for self-administered FSH injection devices in select European markets

Zitoun¹,

Parikh²,

Nijs³

et al. 2019

IJWH

View full text Add to dashboard Cite

PurposeThe purpose of this study was to assess product-specific features for a variety of self-administered injection devices and identify key factors that patients and nurses in select European markets find most important when selecting injection devices for self-administration of recombinant human follicle-stimulating hormone and urinary human follicle-stimulating hormone for fertility/reproductive therapy.Patients and methodsPatients (N=402) in France, Italy, Spain, Germany, the UK, the Netherlands, and Belgium, as well as reproductive/fertility nurses (N=40) in Germany, Italy, France, Spain, and the Czech Republic were surveyed. All patients were previously prescribed a follicle-stimulating hormone (FSH) treatment for either in vitro fertilization or ovulation induction. Patient and nurse preferences for attributes across all injection devices in the market were obtained via an online questionnaire and evaluated using the maximum differential scaling (MaxDiff) and conjoint analyses, which captured the relative importance of the selected FSH injection device attributes to determine specific qualities in overall product preference.ResultsBoth the MaxDiff and conjoint analyses indicated that, for patients and nurses, the ideal FSH injection device would be a highly accurate, multi-use reusable pen injector with a dial-back function that would be easy for both use and education/instruction. Patients and nurses each selected attributes pertinent to their own experiences with the FSH injection device. Categorically, patients valued factors that resulted in minimal impact on daily life, including reduced injection volume to minimize injection-site pain, as well as a reusable device that would be easy to use; nurses placed greater value on a device that would be easy to teach in order to instruct the greatest number of patients while minimizing risk.ConclusionPatient and nurse preferences were aligned on certain selected attributes of the FSH products. Although this study was an unbranded examination of attributes across all injection devices currently in the market, results demonstrated that the preferred product attributes were all characteristics of the Ovaleap® Pen.

show abstract

Section: Introductionmentioning

confidence: 99%

Analysis of patient and nurse preferences for self-administered FSH injection devices in select European markets

Zitoun¹,

Parikh²,

Nijs³

et al. 2019

IJWH

View full text Add to dashboard Cite

show abstract

“…Features of controlled ovarian stimulation other than cost – such as effectiveness, number of injections/comfort level and convenience of administration – may have an impact on patient preference ( Palumbo et al, 2011 , van den Wijngaard et al, 2015 ). These aspects could favour the choice of corifollitropin alfa compared with rFSH.…”

Section: Discussionmentioning

confidence: 99%

Comparative economic study of the use of corifollitropin alfa and daily rFSH for controlled ovarian stimulation in older patients: Cost-minimization analysis based on the PURSUE study

Barrenetxea¹,

García-Velasco²,

Aragón³

et al. 2018

Reproductive Biomedicine & Society Online

View full text Add to dashboard Cite

This study presents an economic assessment of controlled ovarian stimulation in assisted reproductive technology procedures in Spain, comparing the use of corifollitropin alfa and various forms of recombinant follicle-stimulating hormone (rFSH) in women of advanced maternal age. A cost-minimization analysis (CMA) was performed to assess the cost per cycle of controlled controlled ovarian stimulation, including only direct costs associated with the stimulation phase. The CMA was based on the population characteristics, the protocol, and the results obtained from the PURSUE study, taking into account 9 days of controlled controlled ovarian stimulation and 300 IU rFSH/day. The primary analysis included pharmacological costs alone. Different scenarios were evaluated including various doses and possible additional days (0–5) for rFSH. For the alternative analyses, the total costs (direct pharmacological costs, costs of visits and follow-up tests, and any additional pharmacological costs) were considered in both the private and public sectors. Treatment with corifollitropin alfa resulted in a lower pharmacological cost compared with rFSH (€757.25 and €950.30, respectively), creating a saving of approximately -20%. The results of the scenario analyses showed that corifollitropin alfa reduced the pharmacological cost of controlled ovarian stimulation in comparison with daily administration of doses ≥ 250 IU rFSH (considering same daily dose for all days), regardless of the additional days required (7–12 days) (average -€223; range -€488 to -€44). In conclusion, in addition to the efficacy shown in the PURSUE study, the use of corifollitropin alfa results in a decrease in the direct costs associated with controlled ovarian stimulation in older women in Spain.

show abstract

“…Low-impact IVF is currently performed by administering daily FSH stimulation at dosages that are typically 25-50% reduced compared to traditional COH protocols [1,2]. However, with the advent of corifollitrophin alpha (CFA), a long acting FSH stimulant, a new alternative protocol has become possible.…”

Section: Introductionmentioning

confidence: 99%

“…Recent large randomised controlled trials have reported that corifollitrophin alpha (CFA) is an effective stimulant for controlled ovarian hyperstimulation in IVF (COH), producing pregnancy rates equivalent to traditional rFSH, but requiring significantly fewer COH stimulant injections [3,4]. While no RCT study has confirmed a patient preference for once-a-week stimulant over traditional daily rFSH approach, surveys do suggest that women prefer fewer injections provided that this approach does not compromise their IVF outcomes [2].…”

Section: Introductionmentioning

confidence: 99%

Sequential clomiphene/corifollitrophin alpha as a technique for mild controlled ovarian hyperstimulation in IVF: a proof of concept study

Zander-Fox

Lane

Hamilton

et al. 2018

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

Patient preference for a long-acting recombinant FSH product in ovarian hyperstimulation in IVF: a discrete choice experiment

Abstract: The results of this DCE helps us to understand the trade-off women make in their preference for a long-acting rFSH product or a daily-administrated rFSH product in IVF and may support doctors when counselling patients.

Cited by 21 publications

References 26 publications

Analysis of patient and nurse preferences for self-administered FSH injection devices in select European markets

Analysis of patient and nurse preferences for self-administered FSH injection devices in select European markets

Comparative economic study of the use of corifollitropin alfa and daily rFSH for controlled ovarian stimulation in older patients: Cost-minimization analysis based on the PURSUE study

Sequential clomiphene/corifollitrophin alpha as a technique for mild controlled ovarian hyperstimulation in IVF: a proof of concept study

Contact Info

Product

Resources

About